nitrofurantoin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
NO2 - derivatives 1949 67-20-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nitrofurantoin sodium
  • nitrofurantoin
  • furadantin
  • furadantoin
  • nitrofurantoin, macrocrystalline
  • nitrofurantoin monohydrate
A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.
  • Molecular weight: 238.16
  • Formula: C8H6N4O5
  • CLOGP: -0.47
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 1
  • TPSA: 120.73
  • ALOGS: -2.76
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.19 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 47 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 24 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 87 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.57 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.70 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.17 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.97 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 6, 1953 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary tract infection 303.20 10.29 536 32970 223484 50348134
Autoimmune hepatitis 208.13 10.29 101 33405 7418 50564200
Drug ineffective 131.06 10.29 214 33292 819119 49752499
Drug hypersensitivity 122.80 10.29 405 33101 250605 50321013
Jaundice 121.05 10.29 116 33390 26313 50545305
Pulmonary toxicity 100.14 10.29 56 33450 5506 50566112
Cystitis 82.23 10.29 123 33383 44441 50527177
Contraindicated product administered 78.85 10.29 5 33501 148953 50422665
Drug-induced liver injury 78.60 10.29 95 33411 28000 50543618
Infusion related reaction 73.58 10.29 12 33494 169545 50402073
Pulmonary fibrosis 72.26 10.29 85 33421 24352 50547266
Synovitis 69.18 10.29 3 33503 123862 50447756
Lip swelling 63.33 10.29 80 33426 24656 50546962
Rheumatoid arthritis 57.86 10.29 31 33475 202519 50369099
Systemic lupus erythematosus 54.61 10.29 13 33493 140609 50431009
Hand deformity 54.11 10.29 3 33503 100196 50471422
Therapeutic product effect decreased 53.98 10.29 12 33494 136038 50435580
Interstitial lung disease 52.91 10.29 112 33394 53064 50518554
Drug intolerance 52.42 10.29 41 33465 219063 50352555
Off label use 51.45 10.29 153 33353 474273 50097345
Glossodynia 44.25 10.29 11 33495 115558 50456060
Oesophageal spasm 43.75 10.29 24 33482 2272 50569346
Systemic inflammatory response syndrome 43.64 10.29 32 33474 5017 50566601
Heart sounds 42.77 10.29 16 33490 614 50571004
Arthropathy 41.09 10.29 27 33479 157879 50413739
Prolonged expiration 40.67 10.29 16 33490 705 50570913
Injury 39.66 10.29 95 33411 48830 50522788
Oesophageal pain 39.30 10.29 24 33482 2778 50568840
Malaise 38.19 10.29 364 33142 335168 50236450
Wound 35.20 10.29 13 33493 105781 50465837
Treatment failure 35.18 10.29 24 33482 137613 50434005
Multiple sclerosis 34.18 10.29 54 33452 20439 50551179
Hepatic fibrosis 33.96 10.29 23 33483 3179 50568439
Pericarditis 33.16 10.29 6 33500 78683 50492935
Joint swelling 32.78 10.29 71 33435 245215 50326403
Liver function test abnormal 31.63 10.29 82 33424 44257 50527361
Swollen tongue 30.45 10.29 62 33444 28568 50543050
Rales 28.32 10.29 34 33472 9944 50561674
Costovertebral angle tenderness 27.97 10.29 7 33499 65 50571553
Hallucination 27.05 10.29 80 33426 46577 50525041
Alopecia 26.50 10.29 79 33427 244968 50326650
Abdominal discomfort 26.27 10.29 73 33433 231568 50340050
Drug reaction with eosinophilia and systemic symptoms 26.12 10.29 58 33448 28366 50543252
Lymphoedema 25.75 10.29 31 33475 9091 50562527
Acute hepatic failure 25.72 10.29 41 33465 15636 50555982
Product use issue 25.62 10.29 37 33469 149438 50422180
Hypersensitivity pneumonitis 25.39 10.29 17 33489 2305 50569313
Bladder disorder 25.27 10.29 28 33478 7515 50564103
Hepatic cirrhosis 24.85 10.29 43 33463 17534 50554084
Pyelonephritis 24.31 10.29 39 33467 14950 50556668
Change of bowel habit 24.31 10.29 15 33491 1769 50569849
Musculoskeletal stiffness 23.85 10.29 30 33476 128451 50443167
Chromaturia 23.72 10.29 38 33468 14552 50557066
Urosepsis 23.41 10.29 39 33467 15426 50556192
Eosinophilia 23.01 10.29 43 33463 18609 50553009
Cystitis interstitial 22.89 10.29 13 33493 1316 50570302
Cholecystitis chronic 22.75 10.29 30 33476 9639 50561979
Respiration abnormal 22.61 10.29 22 33484 5080 50566538
Emotional distress 22.52 10.29 55 33451 28608 50543010
Atrioventricular block first degree 22.49 10.29 24 33482 6177 50565441
Febrile neutropenia 22.43 10.29 19 33487 97648 50473970
Drug abuse 22.32 10.29 6 33500 59840 50511778
Pollakiuria 22.29 10.29 49 33457 23802 50547816
Neurogenic bladder 22.22 10.29 17 33489 2840 50568778
Liver transplant 21.86 10.29 15 33491 2117 50569501
Urine odour abnormal 21.65 10.29 22 33484 5351 50566267
Hepatic enzyme increased 21.64 10.29 36 33470 137344 50434274
Kidney infection 21.62 10.29 42 33464 18704 50552914
Swelling 21.53 10.29 65 33441 200807 50370811
Multiple sclerosis relapse 21.51 10.29 70 33436 42894 50528724
Hepatitis 21.24 10.29 57 33449 31396 50540222
Appetite disorder 21.01 10.29 23 33483 6091 50565527
Jaundice cholestatic 20.72 10.29 21 33485 5090 50566528
Depressive symptom 20.52 10.29 17 33489 3183 50568435
Hiccups 19.67 10.29 13 33493 1726 50569892
Dysuria 19.59 10.29 52 33454 28452 50543166
Arthralgia 19.55 10.29 191 33315 438511 50133107
Amblyopia 19.54 10.29 7 33499 237 50571381
Acute febrile neutrophilic dermatosis 18.99 10.29 15 33491 2627 50568991
Fracture displacement 18.97 10.29 11 33495 1158 50570460
Anhedonia 18.58 10.29 27 33479 9497 50562121
Colour blindness acquired 18.31 10.29 5 33501 67 50571551
Rectal polyp 18.19 10.29 10 33496 951 50570667
Death 17.91 10.29 134 33372 325245 50246373
Nephrolithiasis 17.79 10.29 57 33449 34636 50536982
Sinusitis 17.70 10.29 56 33450 170502 50401116
Pseudophaeochromocytoma 17.67 10.29 5 33501 77 50571541
Irritable bowel syndrome 17.65 10.29 6 33500 51435 50520183
Abdominal rigidity 17.50 10.29 12 33494 1692 50569926
Swelling face 17.39 10.29 75 33431 52520 50519098
Rash macular 17.34 10.29 39 33467 19238 50552380
Neutropenia 17.23 10.29 46 33460 147919 50423699
Flank pain 17.14 10.29 31 33475 13084 50558534
Subacute cutaneous lupus erythematosus 16.84 10.29 13 33493 2202 50569416
Chronic hepatitis 16.61 10.29 9 33497 831 50570787
Therapeutic product effect incomplete 16.33 10.29 22 33484 91493 50480125
Therapy interrupted 16.18 10.29 39 33467 20113 50551505
Hepatitis acute 16.16 10.29 23 33483 7938 50563680
Cholelithiasis 15.64 10.29 58 33448 37915 50533703
Ureteric obstruction 15.63 10.29 11 33495 1617 50570001
Discomfort 15.62 10.29 30 33476 108350 50463268
Lower urinary tract symptoms 15.54 10.29 4 33502 42 50571576
Oesophageal cancer metastatic 15.51 10.29 5 33501 122 50571496
Muscle injury 15.27 10.29 3 33503 37108 50534510
Eosinophilic pleural effusion 15.21 10.29 4 33502 46 50571572
Hepatic necrosis 15.09 10.29 18 33488 5230 50566388
Tubulointerstitial nephritis 15.07 10.29 32 33474 15179 50556439
Retroperitoneal fibrosis 14.79 10.29 6 33500 287 50571331
Cardiac murmur 14.75 10.29 26 33480 10758 50560860
Intestinal haemorrhage 14.63 10.29 14 33492 3166 50568452
Folliculitis 14.50 10.29 4 33502 39221 50532397
Peripheral swelling 14.28 10.29 79 33427 205857 50365761
Escherichia urinary tract infection 14.13 10.29 25 33481 10370 50561248
Gallbladder disorder 14.09 10.29 33 33473 16709 50554909
Haematuria 13.98 10.29 43 33463 25570 50546048
Nail infection 13.71 10.29 11 33495 1970 50569648
Sensitisation 13.61 10.29 10 33496 1572 50570046
Chronic kidney disease 13.36 10.29 57 33449 39714 50531904
Intentional overdose 13.34 10.29 13 33493 62491 50509127
Bladder irritation 13.05 10.29 5 33501 205 50571413
Product contamination microbial 13.05 10.29 5 33501 205 50571413
Fluid intake reduced 12.97 10.29 13 33493 3109 50568509
Lichen sclerosus 12.71 10.29 8 33498 977 50570641
Wheezing 12.48 10.29 77 33429 61970 50509648
Reperfusion arrhythmia 12.42 10.29 5 33501 234 50571384
Overdose 12.38 10.29 30 33476 99697 50471921
Leukocyturia 12.29 10.29 8 33498 1035 50570583
Hydronephrosis 12.21 10.29 21 33485 8520 50563098
Hyperhidrosis 12.17 10.29 101 33405 89325 50482293
Traumatic lung injury 12.15 10.29 9 33497 1432 50570186
Weight increased 12.14 10.29 81 33425 201810 50369808
Rash 12.13 10.29 377 33129 437094 50134524
Liver injury 12.04 10.29 40 33466 24766 50546852
Clostridium difficile colitis 11.82 10.29 32 33474 17710 50553908
Traumatic liver injury 11.66 10.29 5 33501 275 50571343
Urinary retention 11.63 10.29 41 33465 26149 50545469
Therapy non-responder 11.62 10.29 10 33496 51012 50520606
Urinary incontinence 11.54 10.29 43 33463 28165 50543453
Urinary tract infection bacterial 11.52 10.29 14 33492 4145 50567473
Tracheo-oesophageal fistula 11.34 10.29 6 33500 528 50571090
Granulomatous pneumonitis 11.22 10.29 3 33503 37 50571581
Reflexes abnormal 11.21 10.29 6 33500 541 50571077
Therapeutic response decreased 11.07 10.29 9 33497 47222 50524396
Urine analysis abnormal 11.02 10.29 14 33492 4336 50567282
Helicobacter infection 11.01 10.29 10 33496 49692 50521926
Knee arthroplasty 10.95 10.29 5 33501 35841 50535777
Frustration tolerance decreased 10.94 10.29 16 33490 5658 50565960
Feelings of worthlessness 10.93 10.29 5 33501 321 50571297
Pyrexia 10.89 10.29 329 33177 379874 50191744
Anaemia neonatal 10.86 10.29 5 33501 326 50571292
Walking aid user 10.79 10.29 17 33489 6416 50565202
Retinopathy of prematurity 10.77 10.29 5 33501 332 50571286
Anaemia 10.76 10.29 111 33395 252345 50319273
Hyponatraemia 10.74 10.29 104 33402 96035 50475583
Chest discomfort 10.70 10.29 101 33405 92621 50478997
Product use in unapproved indication 10.67 10.29 40 33466 115779 50455839
Completed suicide 10.62 10.29 48 33458 131841 50439777
Coagulopathy 10.62 10.29 31 33475 17913 50553705
Infection 10.59 10.29 69 33437 172885 50398733
Blood alkaline phosphatase increased 10.53 10.29 51 33455 37475 50534143
Vaginal discharge 10.43 10.29 15 33491 5225 50566393
Hepatic encephalopathy 10.40 10.29 21 33485 9615 50562003
Injection site pruritus 10.38 10.29 7 33499 40404 50531214
Sleep disorder due to a general medical condition 10.38 10.29 18 33488 7353 50564265
Coating in mouth 10.35 10.29 4 33502 168 50571450

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary tract infection 96.76 16.57 91 5422 72263 29496751
Exposure during pregnancy 74.80 16.57 35 5478 8519 29560495
Urosepsis 35.18 16.57 23 5490 10723 29558291
Pulmonary fibrosis 33.94 16.57 26 5487 15556 29553458
Prostatitis 31.38 16.57 16 5497 4681 29564333
Protein total abnormal 31.11 16.57 8 5505 318 29568696
Pulmonary valve stenosis 30.30 16.57 8 5505 353 29568661
Skin depigmentation 29.58 16.57 8 5505 387 29568627
Cardiac murmur 28.86 16.57 17 5496 6596 29562418
Tendonitis 25.96 16.57 17 5496 7944 29561070
Hair colour changes 25.36 16.57 10 5503 1601 29567413
Culture urine positive 24.76 16.57 9 5504 1154 29567860
Porphyria non-acute 23.89 16.57 7 5506 454 29568560
Melanocytic naevus 23.74 16.57 10 5503 1896 29567118
Tooth injury 23.73 16.57 8 5505 822 29568192
Atrial septal defect 23.37 16.57 15 5498 6774 29562240
Open reduction of fracture 23.18 16.57 5 5508 91 29568923
Breast inflammation 22.72 16.57 4 5509 23 29568991
Haematuria 22.53 16.57 34 5479 44105 29524909
Patent ductus arteriosus 21.89 16.57 11 5502 3120 29565894
Plantar fasciitis 20.34 16.57 8 5505 1273 29567741
Eye swelling 20.07 16.57 15 5498 8642 29560372
Foetal exposure during pregnancy 20.06 16.57 28 5485 33839 29535175
Blood chromogranin A increased 19.46 16.57 5 5508 198 29568816
Gastric ulcer 19.32 16.57 18 5495 14043 29554971
Multiple congenital abnormalities 18.81 16.57 6 5507 518 29568496
Carcinoid crisis 18.69 16.57 5 5508 232 29568782
Skin exfoliation 18.57 16.57 22 5491 22623 29546391
Therapy interrupted 18.27 16.57 14 5499 8372 29560642
Bone neoplasm 17.96 16.57 5 5508 270 29568744
Neuroendocrine tumour 17.40 16.57 6 5507 660 29568354
Pulmonary toxicity 17.32 16.57 11 5502 4879 29564135
Craniosynostosis 17.32 16.57 5 5508 308 29568706
Chromaturia 16.85 16.57 16 5497 12786 29556228

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary tract infection 338.71 11.02 497 32291 231099 64234845
Autoimmune hepatitis 193.47 11.02 97 32691 9987 64455957
Drug hypersensitivity 125.99 11.02 333 32455 237482 64228462
Pulmonary toxicity 120.59 11.02 67 32721 8494 64457450
Pulmonary fibrosis 107.56 11.02 102 32686 29776 64436168
Jaundice 86.85 11.02 115 32673 48397 64417547
Cystitis 85.56 11.02 107 32681 42568 64423376
Drug-induced liver injury 79.29 11.02 109 32679 47534 64418410
Lip swelling 73.75 11.02 86 32702 31821 64434123
Drug ineffective 68.77 11.02 210 32578 840037 63625907
Malaise 62.48 11.02 379 32409 395868 64070076
Oesophageal spasm 56.54 11.02 27 32761 2498 64463446
Off label use 55.42 11.02 153 32635 632653 63833291
Drug abuse 49.35 11.02 5 32783 132369 64333575
Infusion related reaction 48.39 11.02 12 32776 164455 64301489
Oesophageal pain 47.22 11.02 26 32762 3237 64462707
Rash 46.30 11.02 394 32394 458155 64007789
Interstitial lung disease 44.83 11.02 130 32658 97602 64368342
Heart sounds 43.67 11.02 15 32773 588 64465356
Urosepsis 43.63 11.02 55 32733 22039 64443905
Systemic inflammatory response syndrome 42.78 11.02 38 32750 10197 64455747
Hypersensitivity pneumonitis 39.35 11.02 23 32765 3209 64462735
Prolonged expiration 39.11 11.02 15 32773 808 64465136
Injury 37.61 11.02 86 32702 55906 64410038
Liver function test abnormal 37.45 11.02 89 32699 59312 64406632
Lymphoedema 35.99 11.02 34 32754 9871 64456073
Multiple sclerosis 35.59 11.02 46 32742 18895 64447049
Febrile neutropenia 34.39 11.02 27 32761 187630 64278314
Contraindicated product administered 33.44 11.02 7 32781 107822 64358122
Bladder disorder 32.78 11.02 29 32759 7738 64458206
Swollen tongue 32.04 11.02 61 32727 34893 64431051
Hallucination 31.63 11.02 95 32693 72693 64393251
Death 30.51 11.02 134 32654 482571 63983373
Rheumatoid arthritis 29.65 11.02 24 32764 164270 64301674
Swelling face 28.38 11.02 80 32708 59086 64406858
Hepatic fibrosis 28.08 11.02 23 32765 5529 64460415
Pyelonephritis 27.96 11.02 39 32749 17227 64448717
Therapeutic product effect decreased 27.63 11.02 12 32776 115339 64350605
Urine odour abnormal 27.51 11.02 22 32766 5114 64460830
Liver injury 27.14 11.02 52 32736 29880 64436064
Rales 25.56 11.02 35 32753 15194 64450750
Chromaturia 25.24 11.02 43 32745 22568 64443376
Neurogenic bladder 24.90 11.02 18 32770 3601 64462343
Neutropenia 24.78 11.02 53 32735 239571 64226373
Drug reaction with eosinophilia and systemic symptoms 24.73 11.02 72 32716 54145 64411799
Completed suicide 24.59 11.02 48 32740 224366 64241578
Fracture displacement 24.45 11.02 12 32776 1179 64464765
Change of bowel habit 23.64 11.02 15 32773 2423 64463521
Cholecystitis chronic 23.09 11.02 26 32762 9261 64456683
Culture urine positive 22.70 11.02 18 32770 4133 64461811
Therapy interrupted 22.23 11.02 38 32750 19998 64445946
Costovertebral angle tenderness 22.16 11.02 7 32781 210 64465734
Multiple sclerosis relapse 22.10 11.02 58 32730 41077 64424867
Amblyopia 21.95 11.02 7 32781 217 64465727
Hand deformity 21.83 11.02 3 32785 62768 64403176
Hepatic cirrhosis 21.80 11.02 44 32744 26254 64439690
Toxicity to various agents 21.69 11.02 103 32685 363410 64102534
Respiration abnormal 21.66 11.02 21 32767 6294 64459650
Dysuria 21.28 11.02 58 32730 41999 64423945
Acute hepatic failure 20.83 11.02 43 32745 26069 64439875
Drug intolerance 20.78 11.02 40 32748 187952 64277992
Hepatitis 20.28 11.02 60 32728 45522 64420422
Emotional distress 19.55 11.02 51 32737 35987 64429957
Urinary tract infection bacterial 19.41 11.02 18 32770 5103 64460841
Cystitis interstitial 19.13 11.02 10 32778 1122 64464822
Intentional overdose 19.07 11.02 11 32777 89933 64376011
Pollakiuria 18.54 11.02 46 32742 31484 64434460
Overdose 18.47 11.02 33 32755 159533 64306411
Flank pain 18.35 11.02 31 32757 16158 64449786
Product use in unapproved indication 18.30 11.02 39 32749 176579 64289365
Femur fracture 18.21 11.02 48 32740 34087 64431857
Pseudophaeochromocytoma 18.15 11.02 5 32783 92 64465852
Rectal polyp 17.95 11.02 10 32778 1274 64464670
Jaundice cholestatic 17.78 11.02 22 32766 8648 64457296
Appetite disorder 17.64 11.02 19 32769 6442 64459502
Depressive symptom 17.42 11.02 16 32772 4480 64461464
Acute febrile neutrophilic dermatosis 17.28 11.02 14 32774 3315 64462629
Colour blindness acquired 17.22 11.02 5 32783 112 64465832
Nail infection 17.01 11.02 11 32777 1836 64464108
Atrioventricular block first degree 17.01 11.02 24 32764 10710 64455234
Arthropathy 16.90 11.02 22 32766 120945 64344999
Tendonitis 16.89 11.02 34 32754 20248 64445696
Anaemia 16.84 11.02 118 32670 378562 64087382
Eosinophilia 16.82 11.02 50 32738 38026 64427918
Liver transplant 16.72 11.02 15 32773 4077 64461867
Prostatitis 16.30 11.02 14 32774 3592 64462352
Kidney infection 16.18 11.02 31 32757 17807 64448137
Haematuria 15.96 11.02 67 32721 60404 64405540
Gallbladder disorder 15.95 11.02 30 32758 17000 64448944
Vomiting 15.84 11.02 379 32409 550738 63915206
Pericarditis 15.79 11.02 6 32782 62510 64403434
Systemic lupus erythematosus 15.74 11.02 10 32778 77602 64388342
Abdominal rigidity 15.69 11.02 12 32776 2615 64463329
Hepatitis acute 15.66 11.02 26 32762 13363 64452581
Treatment failure 15.56 11.02 22 32766 116794 64349150
Lichen sclerosus 15.38 11.02 8 32780 889 64465055
Chronic hepatitis 15.37 11.02 9 32779 1259 64464685
Sensitisation 15.19 11.02 10 32778 1721 64464223
Urticaria 15.01 11.02 127 32661 147190 64318754
Frustration tolerance decreased 14.97 11.02 17 32771 6108 64459836
Urine leukocyte esterase positive 14.95 11.02 13 32775 3390 64462554
Escherichia urinary tract infection 14.92 11.02 24 32764 12013 64453931
Hypotension 14.91 11.02 123 32665 380851 64085093
Lower urinary tract symptoms 14.53 11.02 5 32783 197 64465747
Product use issue 14.50 11.02 35 32753 151680 64314264
Nephrolithiasis 14.47 11.02 52 32736 43631 64422313
Mass 14.42 11.02 27 32761 15249 64450695
Ureteric obstruction 14.32 11.02 11 32777 2411 64463533
Subacute cutaneous lupus erythematosus 14.19 11.02 12 32776 3013 64462931
Cholelithiasis 14.09 11.02 53 32735 45453 64420491
Porphyria non-acute 14.01 11.02 7 32781 714 64465230
Vision blurred 13.91 11.02 86 32702 90230 64375714
Bladder irritation 13.88 11.02 5 32783 226 64465718
Cardio-respiratory arrest 13.64 11.02 18 32770 98375 64367569
Oesophageal cancer metastatic 13.59 11.02 5 32783 240 64465704
Rash macular 13.34 11.02 34 32754 23651 64442293
Protein total abnormal 13.22 11.02 6 32782 494 64465450
Vaginal discharge 13.16 11.02 13 32775 3984 64461960
Calculus bladder 13.08 11.02 8 32780 1212 64464732
Tracheo-oesophageal fistula 12.99 11.02 6 32782 515 64465429
Breast inflammation 12.96 11.02 4 32784 111 64465833
Genital burning sensation 12.90 11.02 5 32783 277 64465667
Nausea 12.79 11.02 504 32284 785296 63680648
Wound 12.78 11.02 12 32776 76465 64389479
Reperfusion arrhythmia 12.73 11.02 5 32783 287 64465657
Traumatic lung injury 12.73 11.02 10 32778 2266 64463678
Wheezing 12.58 11.02 77 32711 80502 64385442
Organising pneumonia 12.54 11.02 19 32769 9036 64456908
Tinnitus 12.49 11.02 42 32746 34091 64431853
Urine analysis abnormal 12.44 11.02 15 32773 5741 64460203
Retroperitoneal fibrosis 12.42 11.02 6 32782 569 64465375
Skin depigmentation 12.35 11.02 7 32781 921 64465023
Therapeutic product effect incomplete 12.34 11.02 21 32767 103461 64362483
Vulvovaginal swelling 12.22 11.02 5 32783 320 64465624
Sinusitis 12.18 11.02 36 32752 145892 64320052
Paraesthesia oral 12.13 11.02 23 32765 13108 64452836
Muscle spasms 12.03 11.02 117 32671 140906 64325038
Cough 12.00 11.02 218 32570 301930 64164014
Fluid intake reduced 11.98 11.02 14 32774 5186 64460758
Nail disorder 11.81 11.02 18 32770 8606 64457338
Chest discomfort 11.77 11.02 100 32688 116006 64349938
Walking aid user 11.40 11.02 15 32773 6266 64459678
Blood chromogranin A increased 11.40 11.02 5 32783 380 64465564
Leukocyturia 11.39 11.02 8 32780 1530 64464414
Weight increased 11.27 11.02 63 32725 213285 64252659
Decreased interest 11.20 11.02 11 32777 3349 64462595
Urinary retention 11.08 11.02 52 32736 49149 64416795
Hepatitis chronic active 11.05 11.02 4 32784 183 64465761
Blood urine present 11.04 11.02 27 32761 18313 64447631

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01XE01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Nitrofuran derivatives
ATC J01XE51 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Nitrofuran derivatives
FDA CS M0014892 Nitrofurans
FDA EPC N0000175494 Nitrofuran Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000892 Anti-Infective Agents, Urinary
CHEBI has role CHEBI:35441 antiinfective agents
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:50908 agente hepatotoxico

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Klebsiella cystitis indication 60867007
Escherichia coli urinary tract infection indication 301011002
Staphylococcus Saprophyticus Urinary Tract Infection indication
Enterobacter Cystitis indication
Enterococcus Urinary Tract Infection indication
Staphylococcus Aureus Urinary Tract Infection indication
Prevention of Bacterial Urinary Tract Infection off-label use
Anuria contraindication 2472002 DOID:2983
Acute hepatitis contraindication 37871000
Vitamin B deficiency contraindication 47903000
Fibrosis of lung contraindication 51615001 DOID:3770
Obstructive hyperbilirubinemia contraindication 59848001
Interstitial pneumonia contraindication 64667001
Optic neuritis contraindication 66760008 DOID:1210
Diabetes mellitus contraindication 73211009 DOID:9351
Chronic hepatitis contraindication 76783007 DOID:2237
Oliguria contraindication 83128009
Cholestatic hepatitis contraindication 95556007
Anemia due to enzyme deficiency contraindication 111577008
Deficiency of glucose-6-phosphate dehydrogenase contraindication 124134002 DOID:2862
Cobalamin deficiency contraindication 190634004
Impaired renal function disorder contraindication 197663003
Drug-induced hepatitis contraindication 235876009
Peripheral nerve disease contraindication 302226006
Pseudomembranous enterocolitis contraindication 397683000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.28 acidic
pKa2 0.0 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucose-6-phosphate 1-dehydrogenase Enzyme WOMBAT-PK
CDGSH iron-sulfur domain-containing protein 1 Unclassified Ki 6.09 CHEMBL

External reference:

IDSource
4018849 VUID
N0000147151 NUI
D00439 KEGG_DRUG
54-87-5 SECONDARY_CAS_RN
17140-81-7 SECONDARY_CAS_RN
4018848 VANDF
4018849 VANDF
C0028156 UMLSCUI
CHEBI:71415 CHEBI
U6Z PDB_CHEM_ID
CHEMBL572 ChEMBL_ID
DB00698 DRUGBANK_ID
CHEMBL1201000 ChEMBL_ID
D009582 MESH_DESCRIPTOR_UI
6604200 PUBCHEM_CID
10917 IUPHAR_LIGAND_ID
488 INN_ID
927AH8112L UNII
221129 RXNORM
181427 MMSL
2320 MMSL
404 MMSL
5179 MMSL
5180 MMSL
5181 MMSL
d00112 MMSL
002852 NDDF
002853 NDDF
002854 NDDF
373543005 SNOMEDCT_US
37978007 SNOMEDCT_US
426476003 SNOMEDCT_US
427332002 SNOMEDCT_US
85343003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nitrofurantoin Macrocrystals HUMAN PRESCRIPTION DRUG LABEL 1 0115-1643 CAPSULE 50 mg ORAL ANDA 25 sections
Nitrofurantoin Macrocrystals HUMAN PRESCRIPTION DRUG LABEL 1 0115-1645 CAPSULE 100 mg ORAL ANDA 25 sections
Nitrofurantoin HUMAN PRESCRIPTION DRUG LABEL 1 0115-2023 CAPSULE 50 mg ORAL ANDA 25 sections
Nitrofurantoin HUMAN PRESCRIPTION DRUG LABEL 1 0115-2024 CAPSULE 100 mg ORAL ANDA 25 sections
Nitrofurantoin (monohydrate/macrocrystals) HUMAN PRESCRIPTION DRUG LABEL 2 0185-0122 CAPSULE 25 mg ORAL ANDA 25 sections
Nitrofurantoin (monohydrate/macrocrystals) HUMAN PRESCRIPTION DRUG LABEL 2 0185-0122 CAPSULE 75 mg ORAL ANDA 25 sections
Nitrofurantoin Macrocrystals HUMAN PRESCRIPTION DRUG LABEL 1 0440-1866 CAPSULE 100 mg ORAL ANDA 26 sections
Nitrofurantoin HUMAN PRESCRIPTION DRUG LABEL 1 0472-1992 SUSPENSION 25 mg ORAL ANDA 19 sections
Nitrofurantoin HUMAN PRESCRIPTION DRUG LABEL 1 0591-3684 CAPSULE 25 mg ORAL ANDA 21 sections
Nitrofurantoin HUMAN PRESCRIPTION DRUG LABEL 1 0591-3684 CAPSULE 25 mg ORAL ANDA 21 sections
Nitrofurantoin HUMAN PRESCRIPTION DRUG LABEL 1 0591-3685 CAPSULE 50 mg ORAL ANDA 21 sections
Nitrofurantoin HUMAN PRESCRIPTION DRUG LABEL 1 0591-3685 CAPSULE 50 mg ORAL ANDA 21 sections
Nitrofurantoin HUMAN PRESCRIPTION DRUG LABEL 1 0591-3686 CAPSULE 100 mg ORAL ANDA 21 sections
Nitrofurantoin HUMAN PRESCRIPTION DRUG LABEL 1 0591-3686 CAPSULE 100 mg ORAL ANDA 21 sections
nitrofurantoin macrocrystals HUMAN PRESCRIPTION DRUG LABEL 1 0904-7025 CAPSULE 100 mg ORAL ANDA 13 sections
nitrofurantoin macrocrystals HUMAN PRESCRIPTION DRUG LABEL 1 0904-7026 CAPSULE 50 mg ORAL ANDA 13 sections
nitrofurantoin macrocrystals HUMAN PRESCRIPTION DRUG LABEL 1 0904-7136 CAPSULE 100 mg ORAL NDA 25 sections
Nitrofurantoin Monohydrate/ Macrocrystalline HUMAN PRESCRIPTION DRUG LABEL 2 10544-086 CAPSULE 75 mg ORAL NDA 28 sections
Nitrofurantoin Monohydrate/ Macrocrystalline HUMAN PRESCRIPTION DRUG LABEL 2 10544-086 CAPSULE 25 mg ORAL NDA 28 sections
Nitrofurantoin Macrocrystals HUMAN PRESCRIPTION DRUG LABEL 1 10544-601 CAPSULE 100 mg ORAL ANDA 24 sections
Nitrofurantion Macrocrystals HUMAN PRESCRIPTION DRUG LABEL 1 12634-415 CAPSULE 100 mg ORAL NDA 24 sections
Nitrofurantoin HUMAN PRESCRIPTION DRUG LABEL 2 13811-719 CAPSULE 25 mg ORAL ANDA 25 sections
Nitrofurantoin HUMAN PRESCRIPTION DRUG LABEL 2 13811-719 CAPSULE 75 mg ORAL ANDA 25 sections
Nitrofurantoin Human Prescription Drug Label 1 16571-740 SUSPENSION 25 mg ORAL NDA AUTHORIZED GENERIC 19 sections
NITROFURANTOIN MACROCRYSTALS HUMAN PRESCRIPTION DRUG LABEL 1 16590-380 CAPSULE 100 mg ORAL ANDA 24 sections
Nitrofurantoin (monohydrate/macrocrystals) HUMAN PRESCRIPTION DRUG LABEL 2 16714-439 CAPSULE 75 mg ORAL ANDA 23 sections
Nitrofurantoin (monohydrate/macrocrystals) HUMAN PRESCRIPTION DRUG LABEL 2 16714-439 CAPSULE 25 mg ORAL ANDA 23 sections
Nitrofurantoin (monohydrate/macrocrystals) HUMAN PRESCRIPTION DRUG LABEL 2 21695-300 CAPSULE 75 mg ORAL ANDA 27 sections
Nitrofurantoin (monohydrate/macrocrystals) HUMAN PRESCRIPTION DRUG LABEL 2 21695-300 CAPSULE 25 mg ORAL ANDA 27 sections
Nitrofurantoin Monohydrate/ Macrocrystalline HUMAN PRESCRIPTION DRUG LABEL 2 33261-160 CAPSULE 75 mg ORAL NDA 28 sections